231 filings
Page 5 of 12
8-K
0n7zh gnw87
24 May 22
Motus GI Announces Positive Topline Data From EU Study of the Pure-Vu System
4:10pm
DEFA14A
iyv6oapp 4win
23 May 22
Additional proxy soliciting materials
4:30pm
8-K
x55p2h
12 May 22
Motus GI Reports First Quarter 2022 Financial Results
4:10pm
8-K
li5k dup5dlbs
21 Apr 22
Regulation FD Disclosure
8:05am
8-K
0r0iz55lnfd43duxc
11 Apr 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:30pm
424B5
orhsz353r5kwefh
29 Mar 22
Prospectus supplement for primary offering
4:20pm
S-8
1k3pvu jw
29 Mar 22
Registration of securities for employees
4:15pm
8-K
j0klisa
29 Mar 22
Motus GI Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
b60mp yfjplw9k
24 Feb 22
Motus GI Granted 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement
8:10am
8-K
918zaun8 iiw974
14 Feb 22
Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System
6:40am
8-K
rhhfk 703j3af6hxo6
16 Dec 21
Motus GI Announces U.S. Patent For The Pure-Vu® System's Automatic Self-Purging Features
8:40am
8-K
t30nn2iiuv
12 Nov 21
Motus GI Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:07am
8-K
525b vhstaun
26 Oct 21
Motus GI Announces Presentation of Results from Independent Study of Pure-Vu System in IBP Patients at the 2021 ACG Annual Scientific Meeting
8:12am
8-K
yz9z05oimuhvzv
8 Sep 21
Motus GI Announces Enrollment of Patients at Second Site in the European Union
8:16am
8-K
wyb k87qsjmyqll
27 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am